Vaccine Responses in Patients With B Cell Malignancies | MicrobiomeTrials← Back to trialsNCT05170399
Vaccine Responses in Patients With B Cell Malignancies
RecruitingPHASE4INTERVENTIONAL
Trial Details
Start: 2022-09-14Est. Completion: 2036-11-15
Enrollment target: 350 participants Locations- National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Other microbiome trials you might be interested in
B-cell Acute Lymphoblastic LeukemiaDiffuse Large B-cell LymphomaBurkitt LymphomaNeuroblastomaEwing Sarcoma
Substudy 01A is part of a platform study. The purpose of this study is to assess the efficacy and safety of zilovertamab…
Los Angeles, United StatesEst. completion Mar 31, 2029
Recurrent Burkitt LymphomaRecurrent High Grade B-Cell Lymphoma With MYC and BCL2 RearrangementsRefractory Burkitt Lymphoma
Refractory High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements
This phase II/III trial tests adding glofitamab to standard of care chemoimmunotherapy in patients with Burkitt and high…
Multiple LocationsEst. completion Nov 1, 2033
LeukemiaLymphomaMultiple MyelomaMyelodysplastic Syndromes (MDS)Myeloproliferative Neoplasm
Cancer and treatment-related cognitive changes, such as thinking or remembering, hinder resumption of normal routine and…
Omaha, United StatesEst. completion Jul 2027